Hsa_circ_0079480 promotes tumor progression in acute myeloid leukemia via miR-654-3p/HDGF axis

Abstract

Circular RNAs (circRNAs) are newly-discovered endogenous non-coding RNAs that have vital functions in regulating gene expression in tumorigenesis. Nonetheless, the function of circRNAs in acute myeloid leukemia (AML) are not yet clarified. In this analysis, hsa_circ_0079480, a novel circRNA, has been identified as being highly expressed in AML. Loss-of-function assays showed that reduction of hsa_circ_0079480 decreased the growth and stimulated apoptosis of AML cells in vitro . Furthermore, miR-654-3p was sponged by hsa_circ_0079480, and hepatoma-derived growth factor (HDGF) was targeted by miR-654-3p with respect to the fundamental mechanism. Moreover, the influence on growth and apoptosis of AML cells stimulated by hsa_circ_0079480 inhibition can be rescued by miR-654-3p inhibitor or HDGF overexpression. In summary, hsa_circ_0079480 is highly expressed in AML and drives by tumor progression via regulation of hsa_circ_0079480/miR-654-3p/HDGF axis, indicating that hsa_circ_0079480 may function as a new treatment target for AML therapy.

Identification of circRNA-miRNA-mRNA Regulatory Network and Autophagy Interaction Network in Atrial Fibrillation Based on Bioinformatics Analysis

“… 30 Wen and collaborators indicated that circ_0079480 might function as a new treatment target for acute myeloid leukemia therapy. 31 Cen et al confirmed that circ_0015004 had a potential oncogenic role in renal cell carcinoma. 32 Therefore, the role of these circRNAs in AF had not been reported.…”

Serum hsa_circ_0079480 is a novel prognostic marker for acute myeloid leukemia

“…Overall, increases in serum hsa_circ_0079480 offer promise as a biomarker associated with AML onset and development, in line with prior evidence for the oncogenic activity of hsa_circ_0079480 in AML. 18 One potential limitation of this analysis is the fact that other cancers and diseases may result in the dysregulation of serum hsa_circ_0079480, suggesting that this circRNA may need to be combined with other clinical details and relevant biomarkers to accurately predict AML patient outcomes. Additionally, further research is required to clarify the mechanistic role of hsa_circ_0079480 as a regulator of AML progression.…”

“…17 In previous studies, hsa_circ_0079480, which is encoded on chr7:16298014-16317851, has been identified as an oncogenic driver of AML capable of promoting tumor progression through the miR-654-3p/HDGF regulatory axis. 18 The clinical importance of serum hsa_circ_0079480 in AML patients, however, has yet to be established, and this study was therefore designed to examine the prognostic value of hsa_circ_0079480 levels in the serum of individuals with AML.…”

Analysis of CircRNAs and CircRNA-Associated Competing Endogenous RNA Networks in β-Thalassemia

“…Mechanistically, circRNA-DLEU2 acted as a sponge to adsorb miR-496, leading to elevated PRKACB expression 14 . CircRNA_0079480 was reported to sponge miR-654-3p, thereby promoting the progression of AML by increasing HDGF expression 15 .…”